Cargando…
Knockout validation of LAMP2A antibodies for immunostaining in human cancer cells
LAMP2A is the rate-limiting factor of chaperone-mediated autophagy (CMA), a unique selective protein degradative pathway. To date LAMP2A antibodies are not knockout (KO)-validated in human cells. We have recently generated human isoform-specific LAMP2A KO cells, and here we assessed the specificity...
Autores principales: | Zhou, Xun, Shirokova, Vera, Kaminskyy, Vitaliy O., Berenger, Eva, Kochetkova, Elena, Norberg, Erik, Genander, Maria, Vakifahmetoglu-Norberg, Helin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392744/ https://www.ncbi.nlm.nih.gov/pubmed/37194363 http://dx.doi.org/10.1080/15548627.2023.2213515 |
Ejemplares similares
-
Quantitative proteomic analysis of temporal lysosomal proteome and the impact of the KFERQ-like motif and LAMP2A in lysosomal targeting
por: Kacal, Merve, et al.
Publicado: (2021) -
Mutant p53 as a Regulator and Target of Autophagy
por: Shi, Yong, et al.
Publicado: (2021) -
Resistant to Targeted Therapy - Aim for Metabolic Liabilities
por: Queiroz, André Lima, et al.
Publicado: (2018) -
Glyoxal as an alternative fixative to formaldehyde in immunostaining and super‐resolution microscopy
por: Richter, Katharina N, et al.
Publicado: (2017) -
Characterization of the Role of the Malate Dehydrogenases to Lung Tumor Cell Survival
por: Zhang, Boxi, et al.
Publicado: (2017)